The future of peptides in the US is about to become clearer. Here’s what you should know

A little-known advisory group to the U.S. Food and Drug Administration will meet this week to consider whether restrictions on certain peptides should be eased. Injectables are popular with wellness influencers and some doctors who say they improve muscle recovery, reduce inflammation, extend life or simply improve your overall health.

The meeting offers an early look at how drug regulators in the second Trump administration will respond to the skyrocketing popularity of non-FDA-approved peptides.

FDA’s Pharmaceutical Compounding Advisory Committee (PCAC) It is planned to meet on Thursday and Friday To review some of the controversial, popular peptide injections and discuss whether compounding pharmacies can dispense them.

Previous FDA panels consisted largely of academics and researchers. In contrast, under the second Trump administration, the current committee consists primarily of healthcare professionals who prescribe, manufacture or promote peptides.

US Secretary of Health and Human Services Robert F. Kennedy Jr. He said he was a “big fan of peptides” and used them himself. He also said he hoped to loosen restrictions but faced some resistance within the FDA. some peptides There is not enough safety data.

This week’s advisory committee meeting represents a pivotal moment in determining whether some of these peptides will move closer to mainstream medical practice or remain largely outside it.

During the two-day meeting, the committee will review seven peptides nominated for inclusion on the FDA’s list. 503A Bulk ListA list of ingredients that pharmacies can use to prepare customized medications for people under certain legal conditions.

Inside briefing documents FDA experts for the meeting say there is a lack of evidence of efficacy and safety to justify allowing pharmacies to make the peptides the panel will review. In general, they recommend that peptides not be added to the 503A Bulk List.

Although the committee’s recommendations often carry significant weight in FDA’s decision-making process, they are advisory rather than binding. It is ultimately the agency’s responsibility to decide whether to follow the recommendations.

What are peptides?

Peptides are short chains of amino acids that are the building blocks of proteins. Some have become important prescription drugs. For example, insulin is a peptide, as are GLP-1 drugs commonly used for diabetes and obesity, such as Ozempic and Wegovy. However, the peptides currently before the committee are different; They are not FDA approved.

Although insulin first therapeutic peptideSome newer peptides used for anti-aging, wound healing, or muscle recovery, synthesized in the 1920s, are still considered to be in their infancy when it comes to research data.

Some experts have expressed concerns about the safety of using emerging peptides, which are still considered experimental. It can often be labeled as “research purposes only” or “not for human consumption.” Many people have accessed these peptides online, sometimes from unknown sources, without consulting a doctor. And most peptides are administered by injection.

Peptide supporters argue that allowing FDA-regulated drug pharmacies to dispense these drugs by prescription would provide a safer alternative to ordering products online from unregulated internet sellers.

Critics counter that moving the compounds to legitimate pharmacies can create the appearance that they have been proven safe and effective, when in many cases data from robust clinical studies remains limited. This tension underlies the upcoming meeting.

Which peptides are being studied?

The peptides covered this week are:

• BPC-157 recommended for the treatment of ulcerative colitis

• KPV for wound healing and inflammatory conditions

• MOTs-C for obesity and osteoporosis

• Emideltide for opioid withdrawal, chronic insomnia and narcolepsy

• Semax for some neurological disorders

The FDA advisory committee “will determine whether to allow access to these substances through legitimate state-licensed compounding pharmacies,” said Scott Brunner, CEO of the Alliance for Pharmacy Compounding. sent an open letter to the committee To support the addition of peptides to the list.

However, he added that because many of these experimental peptides do not have the same catalog of robust clinical trial data as FDA-approved drugs, evaluating them for the 503A Bulk List can be challenging for the committee and the agency.

“The committee generally reviews investigational clinical trials, and if there are supporting investigational clinical trial data, there will be a recommendation to add them to the list of drugs that pharmacies can dispense. These data are not available for many of these peptides,” Brunner said. “And so the FDA will need to use a different lens.”

Unlike FDA approval of a new drug, which requires years of clinical studies to demonstrate its safety and effectiveness, placing it on the 503A Bulks List answers a different regulatory question. It evaluates whether a drug meets certain criteria and allows pharmacists to create the drug from bulk ingredients for patients with valid prescriptions.

“Essentially, this would create a legal pathway for pharmacies to be able to manufacture products containing these ingredients and distribute them to patients,” he said. Jesse DresserFrier Levitt is a partner in the law firm’s Life Sciences Department and chair of the firm’s Pharmacy Practice Group.

“That means if you’re going to buy these products, you have to be seen by a doctor, get a prescription, and then get it from a licensed 503A compounding pharmacy,” Dresser said. “And we’ll see what ultimately happens in this meeting.”

How safe are peptides?

Three years ago, the FDA decided that some peptides should not be combined, citing significant safety concerns, including the risk of life-threatening allergic reactions. The discussion is being revisited at this week’s meeting.

Some experts worry that wider availability of certain peptides through compounding in pharmacies could expose more patients to treatments whose long-term safety profiles remain unclear.

“We do not currently know the long-term effects of many of these peptides, what their toxicity, side effects, or even drug interactions are. FDA approval – Phase 1, 2, and 3 clinical trials – requires companies to conduct extensive clinical studies to determine the safety and effectiveness of the drug. None of the peptides currently being considered for compounding are FDA-approved drugs,” said Edgar Asebey, a life sciences attorney and partner at the law firm Frier Levitt, who chairs the FDA Practice Group.

D., regional medical director for 10X Health, a health and wellness company that offers peptides. Castel Santana said he is confident that most peptides have “minimal or low” associated risk based on his personal experience prescribing. However, he warns that taking more than one peptide at the same time may lead to interactions between them.

“The truth is there are some contradictions in this,” he said.

Santana added that he was “happy” the FDA advisory committee was meeting to discuss the peptides.

However, not all doctors may agree.

As for the meeting, research methods expert and director of the Scripps Research Translational Institute, Dr. “I think this is a disaster because there is no data to support the safety and effectiveness of these peptides,” Eric Topol said during a call with reporters hosted by the Harvard TH Chan School of Public Health in April.

After all, Some experts say it’s unknown how safe certain peptides are without clinical trial data, and safety may vary by substance.

How are they currently regulated?

FDA-approved peptides are regulated in the same way as other approved drugs. However, apart from those approved as therapeutic drugs, the production of some peptides remains largely unregulated. Many are not suitable for distribution through compounding pharmacies, and experts warn that rising demand is fueling an unregulated online market that could be dangerous.

“Patients are taking what purport to be these ingredients or using medications made with investigational-grade active ingredients, and I expect almost every day that there will be some serious patient side effects or a number of patients will become sick or get worse by taking batches of these medications that are not in compliance with FDA standards or contain active ingredients that are not in compliance with FDA standards,” Brunner said.

To combat the risky online market, Brunner said the Pharmaceutical Compounding Association’s advisory committee will recommend peptides for pharmacy compounding that could create a “safer” route for access.

“The FDA should also create a green list of authorized FDA-registered manufacturers of these substances,” Brunner said.

“We argue that pharmacies should only have access to the active ingredient from FDA-registered wholesalers. We believe it is necessary to provide a detailed explanation to the patient who may prescribe one of these drugs that this molecule is not as well characterized as drugs normally dispensed to patients, and that the patient should understand that they may have a higher risk profile and should only be taken under the supervision of a physician,” he said. “And we believe there is a place for mandatory reporting of serious adverse events related to these substances.”

What might the future look like?

If the FDA ultimately allows the compounding of some of these peptides, patients may find it easier to obtain them from licensed compounding pharmacies rather than relying on unregulated sources. Doctors may be more comfortable prescribing them. Compounding pharmacies could see significant new business.

Because there are no FDA-approved versions of these peptides, pharmacies may be the only way people can access these drugs in the future, said Dresser, who represents a number of pharmaceutical pharmacies.

“Likewise, there is no risk of competition because there is no FDA-approved version on the market. There are no limitations on their ability to produce a particular formulation,” he said. “It’s really just a matter of whether they can get a prescription from the prescriber.”

Retired FDA veteran and former deputy commissioner Dr. Janet Woodcock has suggested that the future of regulation of peptides may somewhat reflect how dietary supplements are currently regulated.

“Dietary supplements are taken orally, but they have the same type of regulatory scheme as compounded drugs, meaning the FDA can only intervene with them if they cause harm, as has been shown,” Woodcock said. he said. “They don’t have to have tests or clinical studies or anything to show that these work, but they can’t be harmful and they can’t make disease claims.”

CNN’s John Bonifield contributed to this report.

For more CNN news and newsletters, create an account at: CNN.com